Outcomes in Patients with Mild COVID-19 Treated With Casirivimab and Imdevimab or Bamlanivimab-A Single-Center Retrospective Cohort Study in the Bronx

Background Coronavirus disease 2019 (Covid-19) presents as a mild infection in up to 84% of cases out of which 10% progress to more severe disease requiring hospitalization and 33% to 69% progress to long haulers. The real-world data on the use of anti-severe acute respiratory syndrome coronavirus 2 spike neutralizing monoclonal antibodies, namely casirivimab and imdevimab, as well as bamlanivimab for mild Covid-19 is limited. Methods We conducted a retrospective cohort study on patients who received casirivimab and imdevimab or bamlanivimab for the treatment of mild Covid-19. Results Three hundred forty patients were included in the study with the mean age of the cohort 54.7 +/- 17.5 years, and 36.5% of them were men. Thirty-day outcomes revealed that 300 (88.2%) patients were followed up to 30 days, out of which 243 patients (71.5%) were asymptomatic at 30 days, 57 patients (16.7%) had symptoms at 30 days out of which 9 patients (2.6%) had an ED visit or were admitted because of the worsening of Covid-19 in 30 days and 3 patients (0.9%) died. Conclusions Our study suggests that early infusion with monoclonal antibodies may decrease the development of long haulers. Further studies with randomized-controlled trials are needed to understand more about monoclonal antibodies in the prevention of long-term sequelae especially in the setting of ongoing viral mutations.